Consumer Guide,Compounded drugs are not approved by FDA

The landscape surrounding semaglutide and its compounded forms has been a focal point of discussion and regulatory action, particularly concerning FDA semaglutide compound pharmacy practices. The U.S. Food and Drug Administration (FDA) has issued numerous clarifications and warnings regarding compounded versions of semaglutide, a popular pharmaceutical used for managing type 2 diabetes and, off-label, for weight loss.

It is crucial to understand that compounded drugs are not approved by FDA. Unlike FDA-approved medications, which undergo rigorous review for safety, effectiveness, and quality, compounded semaglutide has not been subjected to this comprehensive evaluation. The FDA has explicitly stated that compounded semaglutide is NOT approved by the FDA and has not been reviewed for its safety, effectiveness, and quality. This distinction is paramount for consumers seeking these treatments.

The FDA has been actively monitoring and addressing concerns related to compounding pharmacies. In many instances, compounding pharmacies were permitted to produce semaglutide and similar drugs during periods of shortage for FDA-approved medications. However, with the resolution of these shortages, the regulatory environment has shifted. The FDA has declared the semaglutide shortage over, and consequently, compounded semaglutide is only available in certain situations. This means that pharmacies can no longer routinely compound medications that are "essentially copies" of FDA-approved drugs, except under specific, authorized circumstances.

The FDA has expressed awareness of fraudulent compounded semaglutide and tirzepatide being marketed with false information on product labels. Furthermore, the FDA has warned of dosing errors with compounded injectable semaglutide, reporting adverse events, some requiring hospitalization, that may be linked to overdoses. This highlights potential risks associated with compounded versions where precise dosing and purity may not be as rigorously controlled as with FDA-approved products.

While FDA-approved semaglutide products like Ozempic and Wegovy have undergone extensive clinical trials and regulatory scrutiny, compounded semaglutide operates under different guidelines. Compounded medications are not FDA approved in the same manner. Compounding pharmacies operate under state boards of pharmacy or, in some cases, as FDA-registered outsourcing facilities. The FDA has clarified policies for these compounders, emphasizing that they must comply with specific sections of the Federal Food, Drug, and Cosmetic Act (e.g., section 503A or 503B) to lawfully market these products.

Recent legal rulings have also impacted FDA semaglutide compound pharmacy operations. Court decisions have supported Novo Nordisk's efforts to protect its intellectual property, leading to restrictions on compounding pharmacies that produce unauthorized copies of their semaglutide medications. These rulings have empowered the FDA to take more direct action against compounders operating outside established guidelines. Consequently, many pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs.

It is important to distinguish between FDA-approved medications and their compounded counterparts. Compounded semaglutide is a non-FDA-approved alternative that emerged to address drug shortages. However, as the FDA continues to refine its oversight, the availability and legality of these compounded products are subject to change.

In summary, while compounding pharmacies played a role in making semaglutide accessible during shortages, the FDA's current stance emphasizes the importance of approved medications. Consumers should be aware that compounded semaglutide has not undergone the same safety and efficacy reviews as FDA-approved versions. The FDA continues to monitor these products and provides guidance to both healthcare providers and the public regarding their use and associated risks. The regulatory framework is evolving, and pharmacies compounding these substances must adhere strictly to FDA guidelines and legal mandates.